WINSTON ROY
Known title: Chief Medical OfficerCIK: 0001751757
Associated companies
Transaction History
| PCRX | ▼ Sell | Open Market | 509 | $18K | 8/2/2023 | View on chart |
| PCRX | ▲ Buy | Grant | 10,950 | $0 | 6/14/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,857 | $70K | 6/7/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,779 | $69K | 6/6/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 476 | $27K | 8/3/2022 | View on chart |
| PCRX | ▲ Buy | Grant | 9,900 | $0 | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,099 | $129K | 6/6/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 6,250 | $215K | 6/6/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,535 | $153K | 6/6/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,300 | $142K | 6/6/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,300 | $81K | 6/6/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 115 | $7K | 6/6/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 3,533 | $214K | 6/6/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 3,650 | $225K | 6/6/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,891 | $118K | 6/6/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 123 | $8K | 6/6/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 10,000 | $482K | 11/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.